XERSXeris Biopharma Holdings, Inc.
Is it safe?
Elevated bankruptcy risk: a balance sheet under strain, heavy debt (BB), and big price swings. Everything else is secondary until this clears.
Elevated financial-distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$1.2M, 90 days to Oct 8, 2026), selling is often routine.
Moderately leveraged. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -96% · now at/near its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can XERS take a bad year?
Xeris Biopharma Holdings, Inc. carries $131M of net debt at 3.06× EBITDA: a load its earnings can carry.
Net debt · as at Q2 2026 · between two and four years of EBITDA, normal for a stable business
- Net debt / EBITDA
- 3.06×
Net debt / EBITDA
- Altman Z-score
- 1.01
Altman Z-score · distress zone, below 1.8
- Interest cover
- 1.30×
Interest cover · operating profit barely covers the interest bill
Details›
- Total debtQ2 2026
- $253M
- Cash and short-term investments
- $122M
- Net debt
- $131M
- EBITDA, trailing twelve months
- $43M
- Operating profit, trailing twelve months
- $37M
- Total debt / EBITDA
- 5.92×
- Annualised volatilitytwo years of daily moves
- 56%
- Worst drawdown on file
- −96%
- Below its 52-week high
- 0.00%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
Ranks #25 of 41 by RyuScore